Given the mixed data, the ten ongoing trials evaluating the safety and efficacy of immunotherapy, CCRT, and novel agents such as PARP inhibitors or anti-TIGIT antibodies for LS-SCLC will serve as a catalyst to defining the role of ICIs within the field of thoracic oncology. The gene discussed is TIGIT; the disease is small cell lung carcinoma.